• Adverse events (AE) and serious adverse events (SAE) [ Time Frame: D-1/D10 of each cycle ]
  AE and SAE with predefined toxicity criteria will be applied using CTCAE version 5.0 criteria, documented before and after each cycle of PIPAC treatment. Surgical complications will be assessed according to Clavien classification and comprehensive complication index (CCI)
• The efficacy [ Time Frame: D0 of each cycle ]
  It will be assessed by the objective histological regression and objective tumor response rate (OTR) according to the new regression system for peritoneal cancer (PRGS, peritoneal regression grade score system). The objective response rate (ORR), the clinical benefit rate (CBR) as defined by RECIST version 1.1 criteria and the relevance of radiological response assessed by CT enterography (CT-PCI score).
• The QoL [ Time Frame: D-1/D10 of each cycle ]
  QoL will be evaluated based on the EORTC questionnaire QLQ-C30 Version 3.0 and visual analogic scale for pain (VAS scale).

• Free plasmatic concentration of paclitaxel [ Time Frame: First 48 hours of each cycle (each cycle is 28 days) ]
  Analysis of free plasmatic concentrations of paclitaxel will be performed at 0.5, 1, 4, 8, 24, 48 hours after the two first PIPAC treatment of each cohort
• Free plasmatic concentration of cisplatin [ Time Frame: First 48 hours of each cycle (each cycle is 28 days) ]
  Analysis of plasmatic concentrations of cisplatin will be performed at 0.5, 1, 4, 8, 24, 48 hours after the two first PIPAC treatment of each cohort
• Urinary platinum concentration [ Time Frame: First 48 hours of each cycle (each cycle is 28 days) ]
  Analysis of urinary Platinum concentration will be performed at 0, 4, 8, 24, 48 hours after the two first PIPAC treatment of each cohort
• Objective histological regression [ Time Frame: Day 0 of each cycle (each cycle is 28 days) ]
  The histologic regression will be assessed by pathologic review of repeated peritoneal biopsies proceeded during laparoscopy before each PIPAC cycle, according to the new regression system for peritoneal cancer.
• Objective tumor response rate [ Time Frame: Screening, Day 10 of Cycle 2, after completion of 3 cycles (each cycle is 28 days) ]
  Objective tumor response rate as defined by RECIST version 1.1 criteria
• Benefit in Quality of Life [ Time Frame: Day-1 and Day 10 of each cycle, after completion of 3 cycles (each cycle is 28 days) ]
  The Quality of Life will be evaluated based on the EORTC questionnaire-C30 Version 3.0
• Benefit in Quality of Life [ Time Frame: Day-1 and Day 10 of each cycle, after completion of 3 cycles (each cycle is 28 days) ]
  The Quality of Life will be evaluated based on visual analogic scale for pain (VAS scale). The VAS scale measures the pain from 0, the minimum pain, to 10 the maximum pain.

• Drug: Nab paclitaxel
  Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
• Drug: Cisplatin
  10.5 mg/m2

Inclusion criteria:

• Informed consent as documented by signature
• ≥18 years,
• psychologically able to follow the trial procedures
• with malignancy disease confined to the abdominal cavity (peritoneal carcinomatosis) from pancreatic, oeso-gastric, epithelial ovarian cancers (platinum resistant only) or primitive peritoneal mesothelioma,
• ECOG 0, 1 or 2,
• Life expectancy > 3 months,
• Not candidate for surgical cytoreduction and IP/HIPEC based on expert multidisciplinary board
• For whom standard therapies have been exhausted or not feasible (>1 line of treatment for platinum resistant epithelial ovarian carcinoma, oesgastric carcinoma, pancreatic carcinoma and primitive peritoneal mesothelioma)

Exclusion criteria:

• Extra-abdominal and intra-abdominal parenchymatous metastatic disease, with the exception of isolated pleural carcinomatosis/effusion or lymph node,
• Bowel obstruction, active gastro-duodenal ulcer or ongoing abdominal infection (bacterial, viral or fungal),
• Chemotherapy or surgery within the last two weeks prior to enrollment,
• Previous intra-abdominal chemotherapy,
• General or local (abdominal) contra-indications for laparoscopic surgery
• Known allergy to cisplatin or other platinum-containing compounds or to nab-paclitaxel,
• Progression while under or within 6 weeks of treatement by platinum
• Severe renal impairment (calculated GFR (CKD-EPI) < 60 mL/min/1.73 m2), myelosuppression (platelet count < 100.000/μl, hemoglobin < 9g/dl, neutrophil granulocytes < 1.500/ml), International Normalized Ratio (INR) > 2, severe hepatic (Serum total bilirubin > 1.5 mg/dl), respiratory or neurologic impairment (grade 3), severe myocardial insufficiency (NYHA class > 2), recent myocardial infarction, severe arrhythmias,
• Pregnancy or breastfeeding, women who can become pregnant must ensure effective contraception.
• Known or suspected non-compliance, inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.